NCT00970346View on ClinicalTrials.gov

Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

November 30, 2009

Conditions
Cystic Fibrosis
Interventions
DRUG

OligoG CF-5/20

Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug

Trial Locations (1)

Unknown

Merthyr Tydfil

Sponsors

Lead Sponsor

AlgiPharma AS
All Listed Sponsors
collaborator

Smerud Medical Research International AS

OTHER

lead

AlgiPharma AS

INDUSTRY

NCT00970346 - Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis | Biotech Hunter | Biotech Hunter